IDEXX Laboratories Stock News

WESTBROOK, Maine , Dec. 22, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Goldman Sachs Healthcare CEOs Unscripte

There are just a couple of weeks left in 2022. I've been tasked with selecting the seven best stocks to buy for 2023.

IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.

This 137% growth for IDXX stock since late 2018 can primarily be attributed to 1 the company's P/S ratio rising 53% to 11.1x trailing revenues, from 7.3x in 2018, 2.

IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - CEO Conference Call Participants Chris Schot

The animal healthcare company beat estimates on the top and bottom lines.

Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEXX Laboratories is operating in an industry with good tailwinds. Over the last decade, IDEXX Laboratories returned 22% annually, but future returns will likely be much lower.

American Pet Products Association, 70% of U.S. households own a pet, as quoted on Yahoo Finance. And Americans are splurging on their pets despite high inflation.

IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.

Over the past 3 months, 7 analysts have published their opinion on IDEXX Laboratories (NASDAQ:IDXX) stock. These analysts are typically employed by large Wall Street banks and tasked with understandin

The Nasdaq is known for high-flying growth stocks, not necessarily buy-and-hold candidates. Electric vehicles, biotechnology, social networking stocks, cloud software companies and the like.

I'm on the hunt for stocks to buy that are primed for a turnaround in the final quarter of 2022 and into 2023.  But what constitutes a turnaround?

Ron Baron's 13F portfolio value decreased from $40.75B to $31.14B this quarter. Click here to read more about BAMCO's holdings and trades for Q2 2022.